BlinkLab (ASX:BB1) is pleased to announce a collaboration with Escuela Superior Politécnica de Chimborazo (“ESPOCH”) in Ecuador to support Proyecto Wiñay, a nationwide study program investigating autism, sensorimotor function, nutrition and gut microbiota in Ecuadorian children and adolescents. Read more: buff.ly/TT2SfdH $BB1.ax #awareness #autismspeaks

We're pleased to welcome Brian Leedman, Chairman of @blinklab (ASX:BB1) to present at the JMM East Coast Investor Lunch. 📅 Tuesday, 28 July 2026 📍 Establishment Ballroom, Sydney 🕧 12:30pm 👉 Register interest for the East Coast Investor Lunch - janemorganmanagement.com.au/…

BlinkLab is pleased to be included in the recent @StockheadAU article "Healthcare innovation pours into the Yarra Valley." Mines in the Vines hosted its second Stocks in the Vines event, showcasing ASX-listed and pre-IPO healthcare companies including BlinkLab. Read the article - stockhead.com.au/health/heal… $BB1.ax #awareness #autismspeaks

Our thanks go out again to the team at Mines in the Vines, for the opportunity to present at the Stocks in the Vines Investor Access Day last week. BlinkLab’s Chairman, Mr Brian Leedman, returned for the latest event in the Stocks in the Vines series, meeting and presenting for investors among a diverse group of companies in biotechnology. Mr Leedman presented on the company's technology, recent achievements, and the latest update on the Company’s regulatory work as it progresses its pivotal FDA 510(k) validation. We thank the Mines in the Vines team for the opportunity to be part of such a well-run, high-quality event, and we encourage you to watch the presentation at the link below 📺 Watch the BlinkLab presentation - youtube.com/watch?v=7fsV_f-n… $BB1.ax #awareness #autismspeaks

Earlier this year, BlinkLab Limited (ASX:BB1) was invited to participate in an event hosted by the Simons Foundation Autism Research Initiative (SFARI) in New York City, where Dr Henk-Jan Boele (Managing Director & CEO) presented alongside other leading experts across autism research, neuroscience, and behavioural analytics brought together for the event. Dr. Boele presented on BlinkLab’s work with smartphone-based neurometric assessments for analysing reflexive facial and behavioural responses, and the session contributed to the broader discussion surrounding objective and quantitative approaches to understanding and assessing neurodevelopmental conditions like autism. At BlinkLab, we often highlight the importance of early diagnoses and intervention, and opportunities like these demonstrate the potential that technology presents for that endeavour; through developments in how behaviour is examined precisely and quantified, as well as by supporting more precise and scalable approaches to behavioural analysis. The invitation to present, as well as the focus of the event itself, reflects the growing global recognition of the importance of developing objective quantitative measures and tools for research in autism, which aligns closely with BlinkLab’s mission and focus on developing accurate smartphone-based neurometric assessments with its platform. Over the coming period, BlinkLab will be sharing some insights from the event, as well as on related milestones that reflect the company’s continued and committed engagement with the global research community. You can read more about SFARI’s workshop event and its presenters at the link below. buff.ly/nwEE8SA $BB1 #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that it has entered into an academic research agreement with Erasmus University Medical Center, a world-renowned medical research institution in The Netherlands. The project is designed to investigate treatment-related changes in behavioural and neurodevelopmental function in patients with Activated PI3K Delta Syndrome, a rare inborn error of immunity that is increasingly recognised as being associated with neurodevelopmental conditions, including autism. Read more: buff.ly/3m6PYwj $BB1.ax

BlinkLab Limited (ASX:BB1) Chairman, Brian Leedman, returned to the Stocks in the Vines Investor Access Day 2026, and provided an update on the company's recent milestones, focusing on the AI-powered smartphone technology designed to diagnose autism and ADHD. 📺 Watch the BlinkLab presentation - youtu.be/7fsV_f-nn0A?si=XFGP… $BB1 #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to provide a recent research report from @morgansAU, where they initiate coverage of the Company, providing an overview of milestones, a comprehensive analysis, and price target. Download report - buff.ly/JwZVzih $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that the Chairman, Mr Brian Leedman, will present today at the Stocks in the Vines – Investor Access Day in the Yarra Valley, Victoria. Read full announcement: buff.ly/zH8lJyX $BB1.ax #awareness #autismspeaks

Brian Leedman, Non-Executive Chairman, outlines BlinkLab Limited (ASX:BB1)’s digital biomarker technology and clinical pathway in the recent @sharecafetweets video. 📺 Watch video - youtu.be/yTftFeKLx-I $BB1.ax #awareness #autismspeaks

Brian Leedman, Non-Executive Chairman, outlines BlinkLab Limited (ASX:BB1)’s digital biomarker technology and clinical pathway on the recent @sharecafetweets video. 📺 Watch video sharecafe.com.au/2026/05/01/… $BB1.ax #awareness #autismspeaks

@blink_lab advances smartphone-based diagnostics for autism and ADHD Brian Leedman, Non-Executive Chairman, outlines BlinkLab’s digital biomarker technology and clinical pathway at Uncovering Hidden Gems. Click below to watch. sharecafe.com.au/2026/05/01/… #BB1

$BB1.ax - @blink_lab (ASX:BB1) is pleased to provide an overview of the Quarterly Activities for the Period Ended 31 March 2026. Read more: buff.ly/L99ooCx #awareness #autismspeaks

$BB1 - @blink_lab (ASX:BB1) is pleased to be attending the Ignite Summit in Singapore this week (21-22 April 2026). 🔊 Dr Henk-Jan Boele (CEO & Managing Director) of BlinkLab will be presenting Today, 22 April 2026, at 10.00 AM, sharing the company story with the broader investor audience. During what is a pivotal period for BlinkLab, we look forward to sharing insights surrounding some of the most significant milestones for the company in its journey toward the validation of our flagship technology, including: Enrollment of the first participant child in our ongoing FDA 510(k) pivotal regulatory trial for BlinkLab Dx1, aimed at being a diagnostic aid for autism, with the study now underway across 10 leading U.S. clinical sites. Selection by the Kingdom of Morocco for a nationwide, government-funded early autism screening program; the first of its kind globally. New partnership with the SHANK2 Autism Foundation in the U.S., expanding our platform into genetically defined neurodevelopmental disorders and rare disease research. If you're attending the Ignite Investment Summit this week, we'd welcome the opportunity to connect with you.

BlinkLab Limited (ASX:BB1) is pleased to have Dr Henk-Jan Boele (CEO & Managing Director) presenting at the Ignite Investments, LLC Summit in Singapore this week (21-22 April 2026). BlinkLab will be presenting Tomorrow, 22 April 2026 at 10.00 AM, sharing the company story with the broader investor audience. During what is a pivotal period for BlinkLab, we look forward to sharing insights surrounding some of the most significant milestones for the company in its journey toward the validation of our flagship technology, including: Enrollment of the first participant child in our ongoing FDA 510(k) pivotal regulatory trial for BlinkLab Dx1, aimed at being a diagnostic aid for autism, with the study now underway across 10 leading U.S. clinical sites. Selection by the Kingdom of Morocco for a nationwide, government-funded early autism screening program; the first of its kind globally. New partnership with the SHANK2 Autism Foundation in the U.S., expanding our platform into genetically defined neurodevelopmental disorders and rare disease research. If you're attending the Ignite Investment Summit this week, we'd welcome the opportunity to connect with you.

It was a pleasure to take part in the Ignite Partners Investment Summit in Hong Kong and share the BlinkLab Limited (ASX:BB1) story with a global audience of investors and industry participants. We thank the Ignite Partners team for the opportunity to be part of such a well-run, high-quality conference. Dr Henk-Jan Boele (CEO & Managing Director) and Brian Leedman (Chairman) shared insights surrounding some of the most significant milestones for the company in its journey toward the validation of our flagship technology. The company has already enrolled the first child participant in the ongoing FDA 510(k) pivotal regulatory trial for BlinkLab Dx1, a diagnostic aid for autism, with the study now underway across 10 leading U.S. clinical sites.

BlinkLab Limited (ASX:BB1) is pleased to announce that it has successfully completed an oversubscribed Placement of ordinary shares to sophisticated and institutional investors; raising a total of A$17.5 million (before costs) at a price of A$0.65 per ordinary share. The successful completion of the Placement represents a critical milestone for BlinkLab as the Company advances toward regulatory approval and commercialisation of its lead product, BlinkLab Dx1, a diagnostic aid for the detection of autism. Read more: buff.ly/I2Hpb8F $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that it has successfully completed an oversubscribed Placement of ordinary shares to sophisticated and institutional investors; raising a total of A$17.5 million (before costs) at a price of A$0.65 per ordinary share. The successful completion of the Placement represents a critical milestone for BlinkLab as the Company advances toward regulatory approval and commercialisation of its lead product, BlinkLab Dx1, a diagnostic aid for the detection of autism. Read more: buff.ly/I2Hpb8F $BB1.ax #awareness #autismspeaks

BlinkLab Limited (ASX:BB1) is pleased to announce that it has successfully completed an oversubscribed Placement of ordinary shares to sophisticated and institutional investors; raising a total of A$17.5 million (before costs) at a price of A$0.65 per ordinary share. The successful completion of the Placement represents a critical milestone for BlinkLab as the Company advances toward regulatory approval and commercialisation of its lead product, BlinkLab Dx1, a diagnostic aid for the detection of autism. Read more: buff.ly/I2Hpb8F $BB1.ax #awareness #autismspeaks

$BB1 - BlinkLab Limited (ASX:BB1)'s Chairman Brian Leedman was pleased to take part in the panel discussion at the Ignite Investments, LLC Conference on “Unlocking Investment in the Life Sciences Sector: What do Asia-based Investors Look For?” The session highlighted several important themes shaping capital flows across the sector: Key Attributes: Identifying the key attributes investors prioritize in small-cap life sciences companies. How have they evolved given current market trends? Cross-border Investment and Licensing Trends: Explaining the implications for international biotech collaboration and deal-making. Pathways to Liquidity: The shifting balance between IPOs, strategic partnerships, and the accelerating resurgence of M&A as an exit. China’s Rising Role: How China’s biopharma sector is redefining competitive leadership. Thank you to the organisers and fellow panellists for a valuable and insightful discussion. $BB1.ax #awareness #autismspeaks